文献速递主动脉疾病

经腰栓塞治疗EVAR后II型内漏的结局

Outcomes of translumbar embolization of type II endoleaks following endovascular abdominal aortic aneurysm repair.
PubMed 文献 · J Vasc Surg · 2021-06-29

术后50.0%瘤体稳定,36.7%初次影像见持续内漏但后续稳定,13.3%需二次干预;无缺血并发症。初次内漏发现时瘤体较大和服用抗血小板药与持续内漏相关。

要点

  • TLE对EVAR后II型内漏伴瘤体增长安全有效,无缺血并发症。
  • 50.0%患者栓塞后瘤体稳定,36.7%持续内漏者随访后稳定。
  • 瘤体较大和服抗血小板药与初次栓塞后持续内漏相关。

核心结论

  • TLE是EVAR后II型内漏伴瘤体增长的安全有效治疗选择。
  • 服抗血小板药及内漏发现时瘤体较大者初次TLE后持续内漏和再干预风险增加。

研究设计与样本

  • 治疗指征为持续II型内漏且瘤体增长≥5 mm。

主要发现

  • 男性24例,平均年龄74.3岁(95%CI 70.9-77.6岁),高血压83.3%、冠心病54.0%。
  • II型内漏发现时平均最大瘤径5.8 cm(95%CI 5.4-6.2 cm),发现至干预平均33.7±28个月,期间平均增长0.84 cm(95%CI 0.48-1.2 cm)。
  • TLE后平均随访19.1个月(95%CI 11.1-27.2个月),28例单用氰基丙烯酸酯胶,2例加弹簧圈。
  • 15例(50.0%)瘤体稳定;11例(36.7%)初次影像见持续内漏,平均21.3±7.2个月后稳定无需再干预。
  • 4例(13.3%)初次TLE后持续内漏需二次干预,其中3例重复TLE后平均17.6±12.9个月稳定,1例需开放瘤体切开及腰血管结扎。

关键数值与推荐

  • 瘤体稳定定义为随访期间增长≤5 mm。
  • 初次栓塞后持续内漏相关因素:内漏发现时瘤径较大(P < .001)和使用抗血小板药(P < .02)。
  • 抗凝治疗不是内漏复发或瘤体增长的显著危险因素。

临床怎么用

  • 对EVAR后II型内漏伴瘤体增长≥5 mm者可考虑TLE。
  • 服抗血小板药或内漏发现时瘤体较大者术后需更密切监测和随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Presence of an endoleak can compromise aneurysm exclusion after endovascular abdominal aortic aneurysm repair (EVAR). Type II endoleaks (T2Es) are most common and may cause sac expansion. We report outcomes of translumbar embolization (TLE) of T2Es following EVAR. METHODS: We conducted a retrospective chart review of patients with T2E after EVAR treated with TLE from 2011 to 2018 at a single academic institution. Treatment indications were the presence of persistent T2E and aneurysm growth ≥5 mm. Sac stabilization was defined as growth ≤5 mm throughout the follow-up period. RESULTS: Thirty consecutive patients were identified. The majority were men (n = 24), with a mean age of 74.3 years (95% confidence interval [CI], 70.9-77.6 years). The most common comorbidities were hypertension (83.3%) and coronary artery disease (54.0%). The mean maximal sac diameter at T2E discovery was 5.8 cm (95% CI, 5.4-6.2 cm). The mean time to intervention from endoleak discovery was 33.7 ± 28 months with a mean growth of 0.84 cm (95% CI, 0.48-1.2 cm) during that time period. The mean follow-up time after TLE was 19.1 months (95% CI, 11.1-27.2 months). Twenty-eight patients were treated with cyanoacrylate glue (CyG) alone, and two were treated with CyG plus coil embolization (CE). There was immediate complete endoleak resolution as assessed intraoperatively, and sac stabilization in 15 cases (50.0%). Eleven patients (36.7%) had evidence of persistent T2E on initial imaging after the embolization procedure; additional follow-up revealed eventual sac stabilization at a mean of 21.3 ± 7.2 months, and therefore, these patients did not require further intervention. In the remaining four cases (13.3%), there was persistent T2E after the initial TLE, requiring a second intervention. Repeat TLE stabilized growth in three of these four patients after a mean of 17.6 ± 12.9 months. One patient required open sacotomy and ligation of lumbar vessels due to continued persistence of the T2E and continued aneurysm growth. There were no ischemic complications related to the embolization procedures. Factors associated with persistent endoleak after initial embolization were larger aneurysm diameter at the time of initial endoleak identification (P < .001) and the use of antiplatelet agents (P < .02). The use of anticoagulation was not a significant risk factor for endoleak recurrence or aneurysm growth after TLE. CONCLUSIONS: TLE of T2E is a safe and effective treatment option for T2E with aneurysm growth following EVAR. Patients taking antiplatelet medication and those with larger aneurysms at the time of endoleak identification appear to be at increased risk for persistent endoleak and need for subsequent procedures following initial TLE. These patients may require more intensive monitoring and follow-up.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Charitable JF, Patalano PI, Garg K, et al. Outcomes of translumbar embolization of type II endoleaks following endovascular abdominal aortic aneurysm repair. J Vasc Surg. 2021. PMID: 34197948. doi:10.1016/j.jvs.2021.06.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。